8-K: Sage Therapeutics Reports Q3 2024 Results, ZURZUVAE Sales Surge, Pipeline Adjustments Made

Sage Therapeutics announced its third quarter 2024 financial results, highlighted by a 49% increase in ZURZUVAE collaboration revenue and strategic pipeline adjustments.

Summary

• Sage Therapeutics reported $11 million in collaboration revenue from ZURZUVAE in Q3 2024, a 49% increase from the previous quarter.
• Approximately 2,000 ZURZUVAE prescriptions were shipped in Q3, a 40% increase from Q2.
• Over 90% of commercial and Medicaid lives are covered by payor policies for ZURZUVAE in postpartum depression (PPD).
• Sage and Biogen will not pursue further development of zuranolone for major depressive disorder (MDD) in the U.S.
• ZULRESSO will be discontinued by December 31, 2024, as Sage focuses on ZURZUVAE.
• The Phase 2 LIGHTWAVE study for dalzanemdor in Alzheimer's Disease did not meet its primary endpoint, and further development in AD is not planned.
• Topline data from the DIMENSION study of dalzanemdor in Huntington's Disease is expected late 2024.
• Biogen terminated its rights to the SAGE-324 program, which Sage will regain full ownership of in February 2025.
• Sage is undergoing a strategic reorganization to support ZURZUVAE launch and focus pipeline development.
• Cash, cash equivalents, and marketable securities totaled $569 million as of September 30, 2024.
• Net loss for Q3 2024 was $93.6 million, compared to $201.6 million in Q3 2023.
• Sage anticipates its current cash position will support operations into 2026.

Sentiment

Score: 7

Explanation: The document shows positive momentum with ZURZUVAE sales and cost reductions, but also includes setbacks in other pipeline programs. The strategic reorganization and focus on ZURZUVAE are positive, but the risks associated with drug development and commercialization remain.

Positives

• ZURZUVAE sales are showing strong growth with a 49% increase in collaboration revenue and a 40% increase in prescriptions shipped compared to the previous quarter.
• Payor coverage for ZURZUVAE is robust, with over 90% of commercial and Medicaid lives covered.
• The company is streamlining operations by discontinuing ZULRESSO and focusing on ZURZUVAE.
• Research and development expenses have decreased significantly compared to the same period in 2023.
• Selling, general, and administrative expenses have also decreased compared to the same period in 2023.
• The net loss has significantly decreased compared to the same period in 2023.
• The company's cash runway is expected to extend into 2026.

Negatives

• Sage and Biogen will not pursue further development of zuranolone for MDD in the U.S.
• The Phase 2 LIGHTWAVE study for dalzanemdor in Alzheimer's Disease did not meet its primary endpoint, leading to the discontinuation of its development in AD.
• Biogen terminated its rights to the SAGE-324 program.
• ZULRESSO will be discontinued by the end of 2024.
• The company experienced a decrease in cash, cash equivalents, and marketable securities from $647 million at June 30, 2024 to $569 million at September 30, 2024.
• Net revenue from sales of ZULRESSO decreased from $2.7 million in Q3 2023 to $0.8 million in Q3 2024.
• Cost of revenues increased from $0.9 million in Q3 2023 to $5.3 million in Q3 2024, including one-time write-offs related to ZULRESSO.

Risks

• The commercial success of ZURZUVAE is crucial for the company's future, and any issues with market acceptance or reimbursement could impact revenue.
• The discontinuation of zuranolone development for MDD and ZULRESSO could impact future revenue streams.
• The failure of the dalzanemdor study in Alzheimer's highlights the risks associated with drug development.
• The termination of the SAGE-324 collaboration with Biogen could impact future development plans.
• The company's strategic reorganization may not achieve the expected cost savings or long-term growth.
• The company's cash runway is dependent on continued collaboration funding and revenue generation.
• There are risks associated with the development and manufacture of product candidates, which could delay timelines or increase costs.

Future Outlook

Sage anticipates its current cash position will support operations into 2026, and operating expenses are expected to decrease in 2025 relative to 2024. The company plans to update cash runway guidance in the near future. They also expect topline data from the DIMENSION study of dalzanemdor in Huntington's Disease later this year.

Management Comments

• We are committed to harnessing the full potential of ZURZUVAE as a transformative treatment for women with postpartum depression, said Barry Greene.
• Our encouraging third quarter results, highlighted by continued growth in revenue and shipments, brings us one step closer to our goal of establishing ZURZUVAE as the standard of care to help more women suffering from this debilitating condition, said Barry Greene.
• Looking forward, we believe that our strategic decisions, including the recent reorganization, will best-position Sage to foster long-term growth and support our mission of better brain health for patients, said Barry Greene.

Industry Context

The announcement reflects a strategic shift in the pharmaceutical industry towards focusing on core assets and streamlining operations. The decision to discontinue ZULRESSO and prioritize ZURZUVAE aligns with the trend of companies focusing on their most promising products. The termination of the SAGE-324 collaboration and the failure of the dalzanemdor study in Alzheimer's highlight the challenges and risks inherent in drug development.

Comparison to Industry Standards

• The 49% increase in ZURZUVAE revenue quarter-over-quarter is a strong performance compared to typical pharmaceutical product launches, which often see slower initial uptake.
• The discontinuation of ZULRESSO is similar to other companies that have streamlined their portfolios to focus on key assets, such as Biogen's decision to focus on Alzheimer's treatments.
• The failure of the dalzanemdor study in Alzheimer's is not uncommon in the industry, where clinical trial success rates are low, with companies like Eli Lilly and Biogen also experiencing setbacks in this area.
• The strategic reorganization and cost-cutting measures are similar to actions taken by other biotech companies facing financial pressures, such as layoffs and pipeline reprioritization seen at companies like Alnylam and bluebird bio.
• Sage's cash runway extending into 2026 is a positive sign, but it is important to compare this to other companies in the same stage of development, such as Neurocrine Biosciences, which has a similar cash position and pipeline.

Related Party Transactions

• Collaboration revenue from sales of ZURZUVAE is a related party transaction with Biogen.

Stakeholder Impact

• Shareholders may view the increased ZURZUVAE revenue and reduced losses positively, but the pipeline setbacks and discontinuation of ZULRESSO may cause concern.
• Employees may be affected by the strategic reorganization, which includes potential job losses.
• Patients with PPD may benefit from the increased availability of ZURZUVAE.
• Customers and suppliers may be impacted by the discontinuation of ZULRESSO.
• Creditors may view the improved financial performance and extended cash runway positively.

Next Steps

• Sage will continue to focus on the commercialization of ZURZUVAE for the treatment of women with PPD.
• The company will complete its strategic reorganization by the end of the fourth quarter of 2024.
• Sage will report topline data from the Phase 2 DIMENSION Study of dalzanemdor in cognitive impairment associated with HD later this year.
• Sage will evaluate potential indications for SAGE-324 after regaining full ownership in February 2025.
• The company plans to update cash runway guidance in the near future.

Key Dates

Keywords

ZURZUVAE, zuranolone, postpartum depression, PPD, dalzanemdor, Huntington's Disease, Alzheimer's Disease, SAGE-324, Biogen, clinical trials, pharmaceuticals, revenue, financial results, pipeline, drug development